Compare CVLT & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVLT | GKOS |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.4B |
| IPO Year | 2006 | 2015 |
| Metric | CVLT | GKOS |
|---|---|---|
| Price | $119.76 | $108.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $194.18 | $122.08 |
| AVG Volume (30 Days) | 659.8K | ★ 1.1M |
| Earning Date | 10-28-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $1,095,835,000.00 | $469,820,000.00 |
| Revenue This Year | $19.22 | $31.15 |
| Revenue Next Year | $12.47 | $24.15 |
| P/E Ratio | $68.76 | ★ N/A |
| Revenue Growth | 22.02 | ★ 30.38 |
| 52 Week Low | $114.47 | $73.16 |
| 52 Week High | $200.69 | $163.71 |
| Indicator | CVLT | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 73.74 |
| Support Level | $120.63 | $104.11 |
| Resistance Level | $125.54 | $107.18 |
| Average True Range (ATR) | 4.13 | 4.15 |
| MACD | 1.73 | 0.94 |
| Stochastic Oscillator | 46.06 | 86.00 |
CommVault Systems Inc provides data and information management software applications and services. The firm sells software licenses and services to large global enterprises, small- and midsize businesses, and government agencies through both its salesforce and its network of reseller partners. Its software solutions include Cleanroom Recovery, HyperScale X, Air Gap Protect, Compliance, Cloud Rewind, and Clumio Backtrack. The company operates in the United States and exports to many other countries.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.